BTIG Reiterates Buy on Denali Therapeutics, Maintains $32 Price Target

Benzinga · 2d ago
BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $32 price target.